Lonza, the world’s leading contract development and manufacturing organization (CDMO), today announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development. With the possibility to send non-GMP powder batches from 1-10 kg and liquid batches from 1-100 L produced within 10 working days, the service helps scientists accelerate timelines, generate critical process data and prepare for GMP manufacturing.
RaMP addresses common early development challenges, including long lead times for custom prototype media, limited small-batch manufacturing options and the need to align early formulation work with future manufacturing requirements.
RaMP is part of Lonza’s end-to-end custom media and buffer solutions offering, supporting customers from media development and screening through non-GMP prototyping and commercial GMP manufacturing. By linking early formulation work with long-term scalability, the service helps simplify development and support manufacturing readiness.
Omar Wahab, Vice President, Head of Bioprocessing, Lonza, commented: “Development teams are under pressure to generate data quickly, make informed process decisions and keep programs moving toward the clinic. RaMP gives customers the possibility of rapid access to custom media in the quantities they need, when they need it. By connecting early screening and process confirmation with future GMP requirements, we help reduce scale-up risk, simplify technology transfer and support a more efficient path to commercialization.”
Delivered through Lonza’s global media development and manufacturing network, RaMP combines rapid turnaround, flexible batch sizes and specialized expertise to help customers advance development with greater confidence while preparing for scale-up and GMP manufacturing.
Further information about Lonza’s custom media capabilities, including development, prototyping and manufacturing support, is available on the Lonza website: Custom media and buffer solutions | Lonza.
Lonza Contact Details
media@lonza.com
About Lonza
Lonza is the world’s leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza’s global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.
Our company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Find out more at www.lonza.com.
Disclaimer
Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this media advisory due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory.
All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to their respective third-party owners and are used for informational purposes only.
